InvestorsHub Logo
Followers 16
Posts 5825
Boards Moderated 0
Alias Born 07/16/2018

Re: LaurieM post# 15942

Sunday, 05/10/2020 7:21:52 PM

Sunday, May 10, 2020 7:21:52 PM

Post# of 21536
EXACTLY, FACTS ARE FACTS!!!!!!!!!


NTRP prints the facts



https://neurotrope.com/neurotrope-announces-top-line-results-from-confirmatory-phase-2-study-of-bryostatin-1-in-moderate-to-severe-alzheimers-disease/

NEW YORK, Sept. 9, 2019 /PRNewswire/ — Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that its confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD did not achieve statistical significance on the primary endpoint, which was change from baseline to Week 13 in the Severe Impairment Battery (SIB) total score.



An average increase in SIB total score of 1.3 points and 2.1 points was observed for the Bryostatin-1 and placebo groups, respectively, at Week 13. There were multiple secondary outcome measures in this trial, including the changes from baseline at Weeks 5, 9 and 15 in the SIB total score. No statistically significant difference was observed in the change from baseline in SIB total score between the Bryostatin-1 and placebo treatment groups.




Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News